4//SEC Filing
Posard Matthew L. 4
Accession 0001415889-24-021305
CIK 0001159036other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:57 PM ET
Size
9.0 KB
Accession
0001415889-24-021305
Insider Transaction Report
Form 4
Posard Matthew L.
Director
Transactions
- Sale
Common Stock
2024-08-13$56.19/sh−10,000$561,930→ 79,755 total - Sale
Common Stock
2024-08-14$57.70/sh−9,881$570,134→ 69,874 total - Sale
Common Stock
2024-08-12$55.72/sh−10,000$557,230→ 89,755 total
Footnotes (3)
- [F1]Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F2]Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Documents
Issuer
HALOZYME THERAPEUTICS, INC.
CIK 0001159036
Entity typeother
Related Parties
1- filerCIK 0001543792
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 4:57 PM ET
- Size
- 9.0 KB